Inactive Instrument

Medivation Inc Stock

Stocks

End-of-day quote Nasdaq Other stock markets
- ^USD	-

16-10-28	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
16-09-07	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE

16-10-28	Eli Lilly and : Drugmaker Sanofi hungry for deals after earnings beat	RE
16-09-07	Exclusive - GW Pharmaceuticals hires investment bank following approaches: sources	RE
16-07-08	Abbott Laboratories : Medtech's 2016 stock surge confronts second-quarter test	RE
16-06-03	Medivation : Ex-Oppenheimer adviser arrested for trading on Pfizer employee's tips	RE
16-06-02	Medivation : sets eligibility date for shareholder consent on board revamp	RE
16-05-25	Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	RE
16-05-25	Lonza : Sanofi moves to oust Medivation board in $9.3 billion takeover fight	RE
16-05-25	Exclusive: Sanofi to unveil challenge to Medivation's board - sources	RE
16-05-10	Astellas Pharma : Medivation succumbs to pressure to explore sale - sources	RE
16-05-09	Exclusive - Medivation succumbs to pressure to explore sale: sources	RE
16-05-05	Medivation : Sanofi ready to up offer for drugmaker Medivation, could oust board	RE
16-05-04	Medivation : Sanofi sees 'strong strategic' fit with U.S. Medivation	RE
16-05-03	Exclusive: Pfizer approaches Medivation about potential takeover - sources	RE

16-10-09	Medivation : New Data Presented at ESMO 2016 Further Demonstrates XTANDITM▼ (enzalutamide) Significantly Improves Time to PSA Progression in Advanced Prostate Cancer, Compared with Placebo	BU
16-09-09	Faruqi & Faruqi, LLP : Announces Filing of a Class Action Lawsuit Against Medivation, Inc.	PR
16-09-06	MEDIVATION SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Medivation, Inc. (MDVN) Over the Proposed Sale of the Company to Pfizer Inc.	PR
16-08-25	Brower Piven Commences An Investigation Into The Proposed Sale Of Medivation, Inc. And Encourages Shareholders To Contact The Firm For Additional Information	BU
16-08-25	Levi & Korsinsky, LLP Announces an Investigation Regarding Whether the Sale of Medivation, Inc. for $81.50 Per Share is Fair to Shareholders	BU

16-10-28	Sanofi : relève ses prévisions pour 2016 et s'envole en Bourse
16-10-27	Sanofi : relève ses prévisions pour 2016 et veut céder ses activités génériques en Europe
16-10-09	Medivation : Neue, im Rahmen der ESMO 2016 präsentierte Ergebnisse belegen zusätzlich, dass XTANDITM▼ (Enzalutamid) die Zeit bis zur PSA-Progression bei fortgeschrittenem Prostatakarzinom im Vergleich zu Placebo signifikant verlängert
16-10-09	Medivation : De nouvelles données présentées au Congrès 2016 de l’ESMO démontrent une fois de plus que XTANDITM▼ (enzalutamide) améliore nettement, par rapport au placebo, le délai avant progression du PSA en cas de cancer de la prostate avancé
16-09-19	Sanofi : poursuit Merck en justice aux USA pour protéger les brevets de Lantus

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	+1.28%	-0.63%	+56.90%	+111.73%	52.88B
WUXI APPTEC CO., LTD.	+8.55%	+17.52%	+72.65%	+82.31%	50.98B
BIONTECH SE	-0.45%	-2.18%	-14.16%	-15.80%	22.81B
INSMED INCORPORATED	+1.28%	+5.09%	-2.30%	+418.34%	22.43B
WUXI BIOLOGICS (CAYMAN) INC.	+2.03%	+7.40%	+28.79%	-13.91%	17.01B
GENMAB A/S	-0.40%	+4.39%	+29.11%	-34.65%	15.91B
EXELIXIS, INC.	+2.98%	+0.82%	+15.64%	+166.21%	13.29B
PHARMAESSENTIA CORPORATION	+5.94%	+14.85%	+134.05%	+296.09%	13.58B
MADRIGAL PHARMACEUTICALS, INC.	-0.71%	+1.98%	+78.88%	+114.48%	11.75B
Average	+2.28%	+5.20%	+44.40%	+124.98%	24.52B
Weighted average by Cap.	+3.00%	+5.40%	+46.44%	+117.44%